{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.72","upperLimit":"88.89","value":"74.1"},{"groupId":"OG001","lowerLimit":"32.42","upperLimit":"65.22","value":"48.7"},{"groupId":"OG002","lowerLimit":"46.29","upperLimit":"71.05","value":"59.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"66"}],"units":"Participants"}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.13","upperLimit":"86.14","value":"68.2"},{"groupId":"OG001","lowerLimit":"15.63","upperLimit":"55.32","value":"33.3"},{"groupId":"OG002","lowerLimit":"34.90","upperLimit":"65.10","value":"50.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"46"}],"units":"Participants"}],"title":"Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.24","upperLimit":"87.84","value":"60.0"},{"groupId":"OG001","lowerLimit":"23.38","upperLimit":"83.25","value":"54.5"},{"groupId":"OG002","lowerLimit":"34.02","upperLimit":"78.18","value":"57.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"21"}],"units":"Participants"}],"title":"Week 48"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.49","upperLimit":"72.90","value":"56.8"},{"groupId":"OG001","lowerLimit":"25.20","upperLimit":"53.76","value":"38.8"},{"groupId":"OG002","lowerLimit":"35.68","upperLimit":"57.59","value":"46.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"86"}],"units":"Participants"}],"title":"Week 24 (LOCF)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.40","upperLimit":"68.08","value":"51.4"},{"groupId":"OG001","lowerLimit":"28.82","upperLimit":"57.79","value":"42.9"},{"groupId":"OG002","lowerLimit":"35.68","upperLimit":"57.59","value":"46.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"86"}],"units":"Participants"}],"title":"Week 48 (LOCF)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"104"}],"units":"Participants"}],"description":"The 24h-UFC concentration results from three samples during screening were averaged to obtain baseline. After baseline, mean 24h UFC was determined at week 24. At Week 4, 8, 16 and 20, mean 24h UFC was determined from two 24 hour urine collections collected on two consecutive days occurring before the visit. At Week 12, 24 and 48, the mean 24h-UFC from three 24 hour urine collections, collected over the week before the visit, was determined. After Week 24, the mean 24h UFC was determined at 12-week intervals until end of study visit, from two 24 hour collections during two consecutive days prior to each respective visit (except at Week 48). UFC was determined by liquid chromatography tandem mass spectroscopy (LC/MS/MS). The normal ranges were determined by the central laboratory's own reference range. All samples, including screening samples, were analyzed by a central laboratory.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 600 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 600 μg for glucose impaired metabolism patients. Mean daily dose category is defined: 600 μg bid group includes all patients whose mean daily dose \\< 1500 μg /day.","id":"OG000","title":"Pasireotide 600 μg"},{"description":"Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg. Mean daily dose category is defined : 900 μg bid group includes all patients whose mean daily dose ≥ 1500 μg /day","id":"OG001","title":"Pasireotide 900 μg"},{"description":"Patients received pasireotide 600 μg or 900 μg BID","id":"OG002","title":"All Patients"}],"paramType":"NUMBER","populationDescription":"LOCF Week 24: last available mean 24h-UFC of at least two samples between and including week 12 and week 24; LOCF Week 48: last available mean 24h-UFC of at least two samples between and including week 12 and week 48. Two-sided 95% confidence intervals for proportions are calculated using the exact method","reportingStatus":"POSTED","timeFrame":"Baseline, week 12, 24 and 48","title":"Percentage of Patients Achieving a Reduction of Mean UFC ≥ 50% From Baseline","type":"SECONDARY","unitOfMeasure":"percentage of participants"}